
Sjögren’s syndrome (SjS) is a systemic autoimmune disorder characterized by lymphocytic infiltration in the salivary and lacrimal glands, resulting in severe dry mouth or eyes [1]. The underlying etiology remains relatively unclear, although genetic, environmental, and/or immunologic factors appear to contribute to the etiology [2].
Numerous induced or spontaneous mouse models that resemble various aspects of SjS have intensively investigated to identify the underlying pathogenesis of SjS in humans [3]. In recent years, several mouse strains, including non-obese diabetic (NOD), MRL/lpr, CD25 knockout strains, and C57BL/6.NOD-Aec1Aec2 (B6DC) have been investigated for the immunopathogenic mechanisms of SjS [3,4]. The B6DC mouse is of a C57BL/6J (B6) genetic background carrying two genetic segments derived from the NOD mouse. The SjS-prone B6DC mouse does not develop type I diabetes as it does not contain the NOD-derived diabetogenic locus, I-Ag7 [5,6]. However, it still demonstrates SjS-like disease phenotype in the B6 genetic background similar to the human SjS disease, such as dry mouth and dry eyes [4]. Thus, the B6DC strain is a useful model to identify candidate genes for SjS-like autoimmune exocrinopathy as it allows the identification of disease-associated genes rather than strain-related genes when compared to B6 [7]. The progress of SjS-like disease in this model can be divided into 3 phases. In phase 1 (0-8 weeks of age), several genetically predetermined physiological abnormalities in organogenesis occur prior to the initiation of disease manifestations [8]. Phase 2 (8-16 weeks of age) is characterized by leukocyte infiltration into the exocrine glands with a concomitant increase of proinflammatory cytokines. In phase 3 (16 weeks of age and older), this mouse strain shows pronounced secretory dysfunctions of the salivary and lacrimal glands, as the hallmark of SjS [9].
Reactive oxygen species (ROS), produced by various cells, such as phagocytes, lymphocytes, cardiomyocytes, hepatocytes, endothelial cells, fibroblasts, and salivary gland cells [10], have useful function serving roles in cell signaling, cell differentiation, cell immunity, etc., when present in low concentrations. These functions are important in maintaining the body’s physiological functions known as redox signaling [11]. However, the high level of ROS is dangerous for living organism as they are detrimental to the major cellular components. When the living organisms stay at oxidative stress (OS) state for a long time, the disease will occur in various systems [12]. ROS is thought to be responsible for oxidatively modified autoantigens in autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, type I diabetes mellitus [13]. SjS, which is an autoimmune disease characterized by inflammatory cell infiltration in the exocrine glands, has also reported to be associated with the increased synthesis of ROS [14-16].
The aim of this study is to identify if the expression of OS in SjS is upregulated even prior to the initiation of SjS-like disease in our mouse model, thereby setting the stage for the full-blown disease phenotype. Therefore, we investigated the expression of malondiadehyde (MDA), which is one of the commonly measured markers for ROS [17], in the submandibular gland (SMX), liver and serum of the 8-week and16-week-old B6DC mice. In addition, the expression of MDA in the plasma of SjS patients was investigated to evaluate if MDA is differentially expressed in patients with SjS in comparison with the level of MDA in healthy individuals.
B6DC and B6 were bred and maintained under specific pathogen-free conditions in the Animal Care Services at the University of Florida. The animals were maintained on a 12 hour light-dark schedule and provided with water and food ad libitum. Both breeding and use of these animals were approved by the University of Florida Institutional Animal Care & Use Committee.
The B6DC female mice were selected at 8 weeks (n=4 per group) and 16 weeks (n=3 per group) of age and age-matched B6 female mice as controls. The mice were euthanized by cervical dislocation after deep anesthetization with isoflurane. The SMX and livers of the mice were freshly excised from individual mice. Approximately 25-30 mg of tissue was weighed and placed into 1.5 mL centrifuge tubes. Radioimmunoprecipitation assay buffer with protease inhibitors was added to each tube with 10 μL of the buffer per mg of tissue. Each tissue was homogenized and sonicated on ice and centrifuged at 1,600×g for 10 minutes at 4°C. The supernatant was placed in a new tube and stored at –80°C for later assay. Blood from the mice was collected with a pipette and placed into a 1.5 mL centrifuge tube without an anticoagulant and allowed to clot for 30 minutes at 25°C. It was then centrifuged at 2,000×g for 15 minutes at 4°C. The serum (upper layer) was transferred to a clean 1.5 mL tube and stored at –80°C before assaying.
Venous blood samples (20 mL/participant) were collected in glass vacutainer tubes containing ethylenediaminetetraacetic acid (EDTA) from five healthy female controls and five SjS patients. Peripheral blood treated with EDTA anticoagulant was utilized to allow for subsequent isolation of peripheral blood leukocytes. To isolate the plasma fraction, whole blood samples were centrifuged at 4,000×g for 10 minutes at 4°C and plasma supernatants were collected and stored at –80°C. SjS diagnosis was based on Modified European-American criteria [18]. The healthy control median age was 34.6 years (range, 25-44 years), and SjS patient median age was 56.8 years (range, 47-67 years). This study was approved by the University of Florida Institutional Review Board (IRB no. 201700998) and a written permission was obtained from all participants in the study by collaborators at the University of Florida Rheumatology & Clinical Immunology clinic.
Samples for MDA measurement from tissue supernatant, serum and human plasma were prepared by thiobarbituric acid reactive substance (TBARS) assay kit (Caymanchemical, Ann Arbor, MI, USA) in accordance with the company’s protocol. Each sample was assayed in triplicate. However, the serum samples of the mice were assayed only once as the amount of the serum was insufficient for triplicate. The fluorescence signals of MDA were read by a plate reader at excitation wavelength of 530 nm and emission wavelength of 550 nm. The MDA concentrations were calculated by the company’s protocol.
Measurements from each sample were displayed as the mean±standard deviation. Significant differences were tested with Mann-Whitney test and unpaired Student’s t-test. The statistical significance level was set at 5% (p<0.05). The tests were performed using GraphPad Prism 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA).
To investigate if OS is higher in the SMX of the SjS-prone mouse, the level of MDA was measured by the TBARS assay kit. This kit forms the MDA-thiobarbituric acid (TBA) adduct by the reaction of one molecules of MDA and two molecules of TBA under high temperature (90°C-100°C) and the MDA-TBA adduct is measured in acidic condition colorimetrically or fluorometrically. A MDA standard was supplied with the kit for the purposes of generating a standard curve. This standard also was utilized as a positive control to validate that MDA was being appropriately detected. Standard curves were linear at each assay and range of R2 was from 0.8829 to 0.9969.
The MDA concentration in the SMX of the B6 mice was 1.57±0.63 μmoL/L at 8 weeks and 2.37±0.56 μmoL/L at 16 weeks. The MDA concentration in B6DC mice was 1.48±0.46 μmoL/L at 8 weeks and 1.77±0.22 μmoL/L at 16 weeks. The MDA concentrations in both 8-week and 16-week-old B6 mice were greater in the B6 than in the B6DC mice. However, the differences were not significant between the groups (Fig. 1A). The MDA concentrations were increased with age in general in both B6 and B6DC groups although a statistically significant increase was not found (Fig. 1B).
The liver was used as a control organ since pathological changes in the liver of B6DC has not been studied or reported to our knowledge. The MDA concentration in the liver of B6 mice was 1.87±0.95 μmoL/L at 8 weeks and 2.86±0.61 μmoL/L at 16 weeks. The MDA concentration in B6DC mice was 2.51±0.99 μmoL/L at 8 weeks while the level of MDA was around 2.24±0.68 μmoL/L at 16 weeks. Although the MDA concentration in B6DC was higher than that of B6 at 8 weeks of age, the difference was not statistically significant (Fig. 1C). There was a trend of increased MDA concentration in B6 mice as they get older (Fig. 1D).
The MDA concentration in the serum of B6 mice was 1.26±0.46 μmoL/L at 8 weeks and 0.60±0.11 μmoL/L at 16 weeks. The MDA concentration in the serum of the B6DC mice was 1.20±0.39 μmoL/L at 8 weeks and 0.54±0.23 μmoL/L at 16 weeks. The statistical analyses were not applied to this comparison because the amount of serum was insufficient to run three independent experiments. The MDA values in the serum of B6 and B6DC at each age group showed little difference although the level of MDA was reduced in both groups at 16 weeks of age (Fig. 2A).
To investigate if the MDA level was upregulated in patients with SjS in comparison with healthy individuals, the plasma samples from healthy subjects and SjS patients were compared for MDA. The MDA concentration of human plasma was 1.75±0.57 μmoL/L in healthy controls and 1.65±0.43 μmoL/L in SjS patients showing no significant difference between the groups (Fig. 2B).
Only a handful of studies on OS in SjS are currently available, which are summarized in Table 1 [14,16,19-22]. Previous studies have mostly investigated human SjS samples [14,16,19-21] and only one study utilized a mouse model of SjS [22]. All studies have clearly shown increased OS biomarkers in SjS [14,16,19-22]. Ryo et al. [19] showed excess levels of two OS markers, 8-hydroxy-2’-deoxyguanosine and hexanoyl-lysine (HEL), in saliva from SjS patients suggesting an involvement of OS in SjS pathogenesis. Others reported an increased level of OS in the labial salivary gland of primary SjS patients, measured by markers of DNA, and lipid oxidation [20]. Cejkova et al. [21] showed an increased the level of MDA in the conjunctival epithelium and Wakamatsu et al. [16] found that increased levels of OS utilizing HEL in tear, and HEL and 4-hydroxy-2-nonenal (4-HNE) in the conjunctival epithelium of SjS patients.
MDA is one of the secondary products that can be formed during lipid peroxidation, such as propanal, hexanal, and 4-HNE [17]. Since Spiteller et al. [23] had reviewed the involvement of lipid peroxidation in a variety of chronic diseases, MDA emerged as one of the most commonly investigated OS markers [17]. However, the MDA evaluation in SjS was found in only two studies. As mentioned above, Cejkova et al. [21] showed an increased level of MDA in the conjunctival epithelium of SjS patients utilizing immunohistochemistry. When Jiang et al. [22] compared the MDA level in the liver of 8-week-old NOD mice following treatments with their plant mixtures, the authors found that the MDA level of NOD mice was statistically greater than that of controls. In our present study, to our surprise, the MDA concentrations in both B6DC and in SjS patients were not statistically different from the levels of MDA in controls. The levels of MDA from 8 weeks to 16 weeks were increased with age in B6 mice in this study, which was only consistent with the report that the OS level increased in the ICR mice with the natural aging [24]. On the other hand, it was interesting that the MDA in the liver, not to be affected by the disease, was a little higher than that of SMX, although it is not significantly different.
In addition, we investigated the MDA concentration in the frozen SMX and the liver of B6DC and B6 mice (not presented). These were the samples that were stored at different time points for a long period time for other projects. The variations among the measured concentrations were significantly high, which appeared to depend on the duration of the sample storage. This clearly indicates that MDA measurements should be applied to fresh samples rather than frozen samples.
Our study utilizing plasma samples, although it was a small number of samples, also indicated the concentration of MDA was not elevated both in the SjS-prone animal and in SjS patients compared to controls. This result was similar with the reports where the level of MDA in human plasma samples of Alzheimer’s disease and in Type I diabetes was not increased [25,26]. However, a review study regarding biomarkers of OS showed elevated MDA levels in the human plasma samples of various diseases, such as amyotrophic lateral sclerosis, Parkinson’s disease, and hypertension [27].
The TBARS assay, used in this study, is the most commonly used method to determine MDA in biological fluids and is convenient to utilize, in particular, for large sample numbers, as it needs only a plate reader instrument in clinical research [28]. The assay is based on a condensation reaction of two molecules of TBA with one molecule of MDA to form a red-colored, visible light-absorbing and fluorescent derivative. The reaction is carried out in acidic solution and elevated temperature of 0-95°C within one hour time course [29]. Our recent search on MDA, because of our current data showing similar responses among samples or minimal differences among our samples with the TBARS assay, has revealed that there is a consensus that the TBARS assay is nonspecific. This has led to a substantial controversy over its use for quantification of MDA from in vivo samples [17]. The numerous commercial easy-to-use kits lack specificity and their significance for clinical research is questionable [27], since TBA may react not only with MDA but also with several other components [30,31]. Moreover, Treatment of biological samples at high temperature in strong acidic conditions for extended incubation time to obtain the condensation product may generate further oxidation of the matrix with obvious overestimation of the results [28,30]. The MDA levels in healthy human plasma measured by the TBARS assay were various from 0.41 μmoL/L to 4.45 μmoL/L [32]. Others reported that TBARS levels, as a biomarker of MDA, in plasma and serum samples of psychiatric patients showed high variations according to the TBA analytic method and were different in the same samples with different analytic method [33].
Several techniques to separate free and total MDA from other components, which are more sensitive and selective compared to the classic TBARS assay, have been developed [28]. High performance liquid chromatography with either ultraviolet–visible spectroscopy or fluorescence detection was suggested as a selective and sensitive method and gold standard among various methods for the MDA evaluation in various biological fluids [27,34,35]. However, this method requires individual sample processing and its validity as a marker for in vivo OS remains uncertain [30]. Recently, it was suggested that gas chromatography-mass spectrometry (GC-MS) and GC-MS/MS methods was specific, precise and sensitive for the quantitative determination of MDA [36].
In conclusion, we investigated the MDA concentration in the SMX, liver, and the serum of the SjS-prone B6DC mice at 8 and 16 weeks for the first time and in human plasma of SjS patients. Our result indicate that the level of MDA was not altered in our mouse model along with SjS patient plasma samples compared with controls, conflicting with other studies, when measured with the TBARS assay. Although it is only hypothetical at this point, it is certainly conceivable that MDA measurement alone may not accurately capture the level of OS in those specimens due to the issues of the assay as mentioned earlier, unless it is combined with more sensitive and reliable measurement methods for OS.
No potential conflict of interest relevant to this article was reported.
![]() |
![]() |